Bristol-Myers Squibb Co.’s $74 billion planned purchase of Celgene Corp. puts it in line to lead the drug industry’s hottest market, cancer, as early as next year.
The combined company will probably overtake front-runner Roche Holding Co. in 2020 with about $29 billion in oncology sales, according to Bloomberg Intelligence. Analysts expect Roche’s cancer sales to slip to about $25 billion by then, based on estimates compiled by BI.
